{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE319nnn/GSE319488/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Mus musculus"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319488"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"RNAseq analysis of peritoneal macrophages from ID8 tumor-bearing high fat diet-fed or control-fed mice after chemotherapy","description":"Overweight/obesity is an established risk factor for ovarian cancer onset, yet its impact on relapses after first-line chemotherapy remains unclear, complicating therapeutic strategies. Peritoneal macrophages, as the most abundant immune population in the peritoneal cavity, serve as the first line of host defense, eliminating pathogens or disseminating tumor cells through phagocytosis in the peritoneal cave. In this study, we found that Impaired peritoneal macrophage phagocytosis correlates with tumor recurrence in the peritoneal cavity of obese mice or overweight patients. To investigate how HFD affects the anti-tumor capacity of peritoneal macrophages, we isolated peritoneal macrophages by flow cytometry from ID8 tumor-bearing mice one week after chemotherapy, when tumor burdens were comparable between groups and performed RNA sequencing to systemic address the underlying mechanisms.","dates":{"publication":"2026/04/13"},"accession":"GSE319488","cross_references":{"GSM":["GSM9518580","GSM9518582","GSM9518581","GSM9518584","GSM9518583","GSM9518585"],"GPL":["13112"],"GSE":["319488"],"taxon":["Mus musculus"]}}